CD274 and neoplasm: Moreover, it has been shown that in a certain group of patients with BRCA1/BRCA2 wild type, they present an immune profile of the tumor showing the expression of PD-1/PDL-1 that would benefit from the treatment of iPARP associated with immunotherapy directed at these two biomarkers.